EPAS1 and non-small cell lung carcinoma: However, our supplementary studies found that there is no significant difference in EPAS1 mRNA and protein expression between NSCLC Osimertinib sensitive and resistance cells (both P > 0.05; Supplemental Fig. 5A, B).